Financial Report and Statutes

MetrioPharm AG Annual Report 2023

Statutes

Statutes of MetrioPharm AG (November 2023, German only)

Investor Relations

Investor-Update QIV 2024 - 2024-Dec-20

Milestones from the COVID-19 trial, Focus on rare diseases: DMD, Outlook 2025: Financing and further development, MetrioPharm AG Company Calendar 2025, MetrioPharm AG informs

» more

Please find our corporate slide-deck as download here:
» MetrioPharm corporate slide-deck

The iMPact project is one of six initiatives selected by the European Commission to work on drug candidates for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19.
» Find out more in the iMPact project film

Newsletter Subscription

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter